Clinical Trials Browser

NCT02621021 2026-04-20

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Phase 2 Recruiting

170 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT05026983 2026-04-16

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Phase 2 Recruiting

35 enrolled

Dermatologic

Melanoma

NCT07223424 2026-04-16

PSI-Immune

Phase 2 Recruiting

880 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT05136196 2026-04-13

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Phase 2 Recruiting

150 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05913388 2026-04-13

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Phase 2 Recruiting

92 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma

NCT06961006 2026-04-13

INTerpath-012

Phase 2 Recruiting

160 enrolled

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04562129 2026-04-01

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Phase 2 Recruiting

29 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT06295159 2026-04-01

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Phase 2 Recruiting

90 enrolled

Dermatologic

Melanoma

NCT06623461 2026-03-27

Canbiome2

Phase 2 Recruiting

128 enrolled

Dermatologic

Melanoma

NCT06223659 2026-03-10

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Phase 2 Recruiting

100 enrolled

Dermatologic

Melanoma, Carcinoma, Merkel Cell

NCT06771544 2026-03-10

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

Phase 2 Recruiting

14 enrolled

Dermatologic

Melanoma

NCT07448831 2026-03-09

NeoSenti

Phase 2 Recruiting

49 enrolled

Dermatologic

Melanoma

NCT07057596 2026-03-06

NEO-TB

Phase 2 Recruiting

19 enrolled

Dermatologic

Melanoma, Neoplasm Metastasis

NCT07449754 2026-03-04

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

Phase 2 Recruiting

45 enrolled

Dermatologic

Melanoma

NCT07072728 2026-03-03

Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder

Phase 2 Recruiting

87 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologic

Adjustment Disorders, Breast Neoplasms, Kidney Neoplasms, Melanoma, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04771520 2026-03-02

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Phase 2 Recruiting

50 enrolled

DermatologicGastrointestinalSarcomaThoracic

Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT06999980 2026-02-19

Neo IRENIE

Phase 2 Recruiting

494 enrolled

Dermatologic

Melanoma

NCT04594187 2026-02-17

MelPORT

Phase 2 Recruiting

168 enrolled

Dermatologic

Melanoma

NCT05155033 2026-02-17

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Phase 2 Recruiting

78 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT06330064 2026-02-12

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Phase 2 Recruiting

520 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Recurrence, Colorectal Neoplasms, Endometrial Neoplasms

NCT07230613 2026-02-11

NEOREM-NEO-1

Phase 2 Recruiting

50 enrolled

Dermatologic

Melanoma

NCT06548789 2026-02-06

Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED

Phase 2 Recruiting

35 enrolled

Dermatologic

Melanoma

NCT06953089 2026-02-06

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

Phase 2 Recruiting

492 enrolled

DermatologicGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms

NCT03340129 2026-02-02

ABC-X

Phase 2 Recruiting

218 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06365619 2026-01-29

NeoRelapse

Phase 2 Recruiting

25 enrolled

Dermatologic

Melanoma

NCT06172478 2026-01-28

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 2 Recruiting

740 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07349303 2026-01-21

NEOPRIME

Phase 2 Recruiting

30 enrolled

Dermatologic

Melanoma

NCT05704647 2026-01-14

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

Phase 2 Recruiting

30 enrolled

Dermatologic

Melanoma

NCT05779423 2026-01-06

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Phase 2 Recruiting

37 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT05428007 2026-01-05

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2 Recruiting

105 enrolled

Dermatologic

Melanoma

NCT05830058 2026-01-05

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Phase 2 Recruiting

32 enrolled

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT06703398 2025-12-23

MIZAR-003

Phase 2 Recruiting

98 enrolled

Dermatologic

Melanoma

NCT07285044 2025-12-22

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Phase 2 Recruiting

27 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidMyeloidPlasma cellThoracic

Amyloidosis, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Lung Neoplasms, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Lymphoma, Mantle-Cell

NCT04996823 2025-12-04

Axitinib + Ipilimumab in Advanced Melanoma

Phase 2 Recruiting

25 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT06265285 2025-12-04

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Phase 2 Recruiting

50 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Colorectal Neoplasms

NCT06319196 2025-12-03

ClearMe

Phase 2 Recruiting

54 enrolled

Dermatologic

Melanoma

NCT07237100 2025-11-19

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Phase 2 Recruiting

10 enrolled

CNSDermatologic

Melanoma, Neurofibromatoses

NCT07155317 2025-11-12

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Phase 2 Recruiting

99 enrolled

Dermatologic

Melanoma

NCT07215182 2025-10-10

BEFAST

Phase 2 Recruiting

20 enrolled

Dermatologic

Melanoma

NCT03915678 2025-10-06

AGADIR

Phase 2 Recruiting

247 enrolled

BreastDermatologicGastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT06887088 2025-10-01